- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04833998
Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine (TACX Care)
Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine: TACX Care Trial
Hand-foot syndrome (HFS) is a very common adverse event of many chemotherapeutic agents, especially capecitabine. The HFS can considerably interfere patient quality of life (QoL).
The current treatments for hand-foot symptoms no have demonstrated 100% efficacy. And, the dose reduction and treatment interruption are recommended for treatment of HFS.
It is known that hydration improves the degree of hand-foot syndrome, as it improves moisture retention and maintain hydration, thereby reducing further desquamation and decreasing infection risks. But so far there is no evidence of a cream that improves incidence. Besides that, clinical trials evaluating the use of urea-based moisturizer in patients treated with capecitabine have not shown efficacy in preventing hand-foot syndrome.
The purpose of this study is to evaluate the effectiveness of moisturizer based on Thoitaine, Aloe Vera and Calendula compared to placebo in the prevention of SMP of any degree, in patients using Capecitabine.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Flávia Viécili Tarcha, MD
- Phone Number: +55 11 99700-0316
- Email: flavinhavt@yahoo.com
Study Contact Backup
- Name: Alayne Domingues Yamada, PhD
- Phone Number: +55 11 98141-7613
- Email: alayne.pesquisa@ibcc-mooca.org.br
Study Locations
-
-
-
São Paulo, Brazil, 03102002
- Recruiting
- IBCC Oncologia
-
Contact:
- Flávia Viécili Tarcha, MD
- Phone Number: +55 11 99700-0316
- Email: flavinhavt@yahoo.com
-
Contact:
- Alayne Domingues Yamada, PhD
- Phone Number: +55 11 98141-7613
- Email: alayne.pesquisa@ibcc-mooca.org.br
-
Principal Investigator:
- Flávia Viécili Tarcha, MD
-
Sub-Investigator:
- Felipe José Silva Melo Cruz, PhD
-
Sub-Investigator:
- Lilian Arruda do Rêgo Barros, MD
-
Sub-Investigator:
- Larissa Carvalho Lopes de Paula, MD
-
Sub-Investigator:
- Luana Carolina Ferreira Fiuza Silva, MD
-
Sub-Investigator:
- Renata Tortato Meneguetti, MD
-
Sub-Investigator:
- Lin I Ter, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥18 years of age
- Patients with gastrointestinal tumors or breast cancer who will be treated with capecitabine
- Indication of adjuvant or palliative treatment with capecitabine
- Eastern Cooperative Oncology Group (ECOG) 0-2
- Information of the patient and signature of the informed consent form by the patient or her legal representative.
Exclusion Criteria:
- Previous chemotherapy with capecitabine
- Pre-existing patients with neuropathies
- Patients with known allergic reactions to any of the ingredients of the investigational product
- Patients with dermatological conditions that affect the hands or feet
- Patients with rectal neoplasia and indication for neoadjuvant treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo will be cream without the active ingredient.
It will be matched in appearance, smell, consistency, and color to Extremecare topical cream.
Patients will be instructed to apply the placebo cream to the hand and feet.
|
Placebo cream will be supplied as 120g use individual tubes to be applicated in the hand and feet twice a day (once in the morning and once in the evening) during the fifth cycle of capecitabine therapy.
|
Experimental: Extremecare
Extremecare is a moisturizing cream based on Thoitaine, Aloe Vera and Calendula for topical use.
Patients will be instructed to apply the moisturizing cream to the hand and feet.
|
The product under investigation (Extremecare) will be supplied as 120g use individual tubes to be applicated in the hands and feet twice a day (once in the morning and once in the evening) beginning with the first cycle of capecitabine and continuing until the end of the fifth cycle of chemotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients presenting Hand-foot Syndrome (HFS) any grade secondary to capecitabine therapy.
Time Frame: Up to 15 weeks
|
Number of Patients who developed Hand-foot Syndrome (HFS) by Toxicity Grade.
The incidence and severity of hand-foot syndrome (HFS) developed during chemotherapy will be defined by using the grading system for HFS per the NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 for all patients assigned who received at least 1 cycle of capecitabine.
Investigators assess and fill the grading into the case report form every visit.
|
Up to 15 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the signs of hand-foot syndrome
Time Frame: Baseline and 1-2-3-4-5 cycles of capecitabine-containing chemotherapy (each cycle is 21 days)
|
Digital Photos will be taken of the hands and feet at 21 day intervals until the fifth cycles of capecitabine-containing chemotherapy ended to evaluate Erythema, desquamation, edema, ulceration, vesicopustules.
|
Baseline and 1-2-3-4-5 cycles of capecitabine-containing chemotherapy (each cycle is 21 days)
|
Incidence of capecitabine dose modifications (dose delay and dose reductions) due to toxicity.
Time Frame: Up to 15 weeks
|
Determined by the number of patients who required a toxicity-related, dose reduction of capecitabine during active treatment at each cycle where a dose reduction occurred
|
Up to 15 weeks
|
Quality of Life as Measured by Dermatology Life Quality Index (DLQI)
Time Frame: Up to 15 weeks
|
Dermatology Life Quality Index (DLQI) consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week.
The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much).
The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
It is self explanatory and is usually completed in one or two minutes.
|
Up to 15 weeks
|
Incidence of cessation of capecitabine therapy
Time Frame: Up to 15 weeks
|
Cessation of capecitabine thereby because any toxicity
|
Up to 15 weeks
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01629018.1.0000.0072
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hand-foot Syndrome
-
Universitas SriwijayaActive, not recruitingCapecitabine | Hand and Foot Syndrome | Hand and Foot Skin ReactionIndonesia
-
China-Japan Friendship HospitalCompleted
-
Jessa HospitalHasselt UniversityRecruitingHand-foot Syndrome | Hand-foot Skin ReactionBelgium
-
Quanta MedicalNAOS Institute of Life ScienceCompletedGrade 2 Hand-foot SyndromFrance
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
China Medical University HospitalNot yet recruiting
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHand-foot SyndromeChina
-
Nan xuCompleted
-
Heinrich-Heine University, DuesseldorfTerminatedThe Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients (BRIMOCAN)Hand-foot SyndromeGermany
-
Mahidol UniversitySiriraj HospitalRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States